Utz J P, Patel A M, Edell E S
Division of Thoracic Diseases and Internal Medicine, Mayo Medical Center, Rochester, Minn. 55905.
Chest. 1993 Oct;104(4):1012-6. doi: 10.1378/chest.104.4.1012.
Metastatic spread to subcarinal lymph nodes in patients with bronchogenic carcinoma generally indicates unresectability. Transcarinal needle aspiration of the main carina (TCNA) has been used to obviate the need for more invasive procedures, particularly thoracic surgery. Of 510 transbronchial needle aspirations performed at our institution from 1983 to 1991, 88 (17 percent) were from the main carina in patients with bronchogenic carcinoma. We reviewed these 88 TCNA procedures to assess our experience with TCNA in the staging of lung cancer. The TCNA results were positive in 32 of 88 (36 percent) patients (20 non-small-cell cancers, 12 small-cell lung cancers). Following bronchoscopy, TCNA was the only evidence of unresectability in all 20 patients with non-small-cell lung cancer and was the only mode of diagnosis in 5 of 12 (42 percent) patients with small-cell lung cancer. Thirteen patients with non-small-cell lung cancer and positive TCNA also had positive bronchial secretion cytologic studies. Five of these patients had further subcarinal sampling and in all cases metastatic involvement was confirmed. TCNA was positive in 29 of 67 (43 percent) patients with radiographic evidence of mediastinal adenopathy. Of the remaining 38 patients with radiographic evidence of mediastinal adenopathy and negative TCNA results, 23 patients had further mediastinal sampling with mediastinoscopy or thoracotomy and in all cases mediastinal spread of cancer was established. Nineteen of 58 (33 percent) patients with an endoscopically normal-appearing main carina had a positive TCNA, while 13 of 30 (43 percent) patients with broadening or widening of the main carina had positive TCNA results. There were no complications. We conclude that TCNA is often a safe and useful staging modality in patients with bronchogenic carcinoma.
支气管源性癌患者出现隆突下淋巴结转移通常提示无法切除。经隆突穿刺主隆突(TCNA)已被用于避免进行更具侵入性的操作,尤其是胸外科手术。1983年至1991年在我们机构进行的510次经支气管针吸活检中,88次(17%)是对支气管源性癌患者的主隆突进行的。我们回顾了这88例TCNA操作,以评估我们在肺癌分期中使用TCNA的经验。88例患者中有32例(36%)的TCNA结果为阳性(20例非小细胞癌,12例小细胞肺癌)。支气管镜检查后,在所有20例非小细胞肺癌患者中,TCNA是无法切除的唯一证据,在12例小细胞肺癌患者中有5例(42%)是唯一的诊断方式。13例非小细胞肺癌且TCNA阳性的患者支气管分泌物细胞学检查也呈阳性。其中5例患者进行了进一步的隆突下采样,所有病例均证实有转移累及。67例有纵隔淋巴结肿大影像学证据的患者中有29例(43%)TCNA阳性。其余38例有纵隔淋巴结肿大影像学证据且TCNA结果为阴性的患者中,23例患者进行了纵隔镜检查或开胸手术进一步纵隔采样,所有病例均证实有纵隔癌转移。58例内镜下主隆突外观正常的患者中有19例(33%)TCNA阳性,而30例主隆突增宽或变宽的患者中有13例(43%)TCNA结果阳性。无并发症发生。我们得出结论,TCNA对于支气管源性癌患者通常是一种安全且有用的分期方法。